InspireMD, Inc.

Listed Company

NSPRCIK 0001433607NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$8.98M

Net Income

$-48.79M

Total Assets

$69.40M

Equity

$55.20M

Shares Out

46.84M

Op. Cash Flow

$-35.10M

NSPR$0.72−69.33% · past yearDBEQ Basic

Daily closing prices

Business

InspireMD is a medical device company developing and commercializing carotid artery stents based on proprietary MicroNet mesh technology to prevent embolic events during and after stenting procedures. Its portfolio includes CGuard EPS, marketed internationally through distributors in over 30 countries, and CGuard Prime, which received FDA premarket approval in June 2025 and is sold in the U.S. through a direct sales force. The company is expanding its product platform with the SwitchGuard neuroprotection system and investigating new clinical applications including acute ischemic stroke treatment, supported by completed and ongoing clinical trials demonstrating safety and efficacy outcomes.

Summary from 10-K filed 2026-03-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
REVENUES	9	7	6	5	4
COST OF REVENUES	6	6	4	4	4
GROSS PROFIT	3	2	2	1	754,000
Research and development	15	14	8	8	5
Selling and marketing	17	6	4	4	3
General and administrative	21	15	11	8	7
Total operating expenses	52	35	23	20	15
LOSS FROM OPERATIONS	−50	−34	−21	−19	−15
FINANCIAL INCOME, net:	891,000	2	1	250,000	−157,000
LOSS BEFORE TAX EXPENSES	−49	−32	−20	−18	−15
TAX EXPENSES	63,000	59,000	65,000	28,000	45,000
NET LOSS	−49	−32	−20	−18	−15
NET LOSS PER SHARE - basic	−0.76	−0.76	−0.82	−2.35	−2.03
NET LOSS PER SHARE - diluted	−0.76	−0.76	−0.82	−2.35	—
WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic	64	42	24	8	7
WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - diluted	64	42	24	8	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2025 2025-05-31	FY 2024 2024-12-31	FY 2024 2024-10-31	FY 2023 2023-12-31
Cash and cash equivalents	9	—	19	—	10
Marketable securities	45	—	16	—	29
Trade, net	2	—	2	—	2
Other	400,000	—	682,000	—	648,000
Prepaid expenses	1	—	1	—	578,000
Inventory	3	—	3	—	2
TOTAL CURRENT ASSETS	61	—	41	—	44
Long term deposit	442,000	—	426,000	422,000	—
Property, plant and equipment, net	4	—	2	—	1
Operating lease right of use assets	3	302,000	2	—	1
Fund in respect of employee rights upon retirement	1	—	1	—	951,000
TOTAL NON-CURRENT ASSETS	8	—	6	—	3
TOTAL ASSETS	69	—	47	—	48
Trade	1	—	1	—	939,000
Other	9	—	6	—	5
TOTAL CURRENT LIABILITIES	11	—	8	—	6
Operating lease liabilities net of current maturities	2	—	2	—	1
Liability for employee rights upon retirement and others	1	—	1	—	1
TOTAL LONG-TERM LIABILITIES	3	—	3	—	2
TOTAL LIABILITIES	14	—	11	—	8
COMMITMENTS AND CONTINGENT LIABILITIES	—	—	—	—	—
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2025 and 2024; 43,532,281 and 26,611,033 shares issued and outstanding at December 31, 2025 and 2024, respectively	4,000	—	3,000	—	2,000
Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at December 31, 2025 and 2024; 1,718 shares issued and outstanding at December 31, 2025 and 2024, respectively	—	—	—	—	—
Additional paid-in capital	357	—	290	—	261
Accumulated deficit	−302	—	−254	—	−222
Total equity	55	—	36	—	40
Total liabilities and equity	69	—	47	—	48

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	476,000	280,000	232,000	188,000	—
Gain from sale of property, plant and equipment	−14,000	—	−6,000	—	−1,000
Change in fair value of marketable securities, net of interest received	−359,000	−894,000	−739,000	—	—
Change in liability for employees rights upon retirement	20,000	163,000	89,000	−57,000	—
Other financial income	−133,000	−51,000	58,000	131,000	8,000
Change in operating right of use asset and operating leasing liability	554,000	−144,000	62,000	−60,000	−14,000
Share-based compensation expenses	12	10	4	2	2
Gain on amounts funded in respect of employee rights upon retirement, net	−299,000	−91,000	−16,000	—	—
Increase in prepaid expenses	−236,000	−482,000	77,000	7,000	−188,000
Decrease (increase) in trade receivables	−596,000	232,000	−770,000	190,000	−748,000
Decrease (increase) in other receivables	282,000	−34,000	−435,000	−48,000	−19,000
Increase in inventory	−826,000	−464,000	−485,000	−478,000	272,000
Increase in trade payables	1,000	315,000	280,000	−234,000	657,000
Increase in other payables	2	1	532,000	958,000	−35,000
Net cash used in operating activities	−35	−22	−16	−16	−13
Purchase of property, plant and equipment	−2	−1	−381,000	−473,000	−344,000
Proceeds from sale of property, plant and equipment	15,000	—	12,000	—	—
Investment in long-term deposit	—	−426,000	—	—	—
Investments in marketable securities	−57	−14	−35	—	—
Proceeds from matured marketable securities	28	29	6	—	—
Amounts funded in respect of employee rights upon retirement	−91,000	−87,000	−79,000	−86,000	−113,000
Amounts withdrawn in respect of employee rights upon retirement	370,000	—	—	—	—
Net cash provided by (used in) investing activities	−31	13	−16	8	−22
Proceeds from exercise of warrants, net of $1,000 issuance costs	17	17	—	—	—
Proceeds from issuance of shares and pre-funded warrants, net of $ 3,148 and $81 issuance costs, respectively	39	2	—	—	—
Net cash provided by financing activities	56	18	38	−140,000	35
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	117,000	51,000	−58,000	−131,000	−8,000
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	−10	9	5	−7	−641,000
Acquisition of right-of-use assets by means of lease liabilities	994,000	1	419,000	835,000	91,000
Non-cash purchase of property and equipment	28,000	189,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is InspireMD, Inc.'s CIK number?

InspireMD, Inc.'s SEC CIK number is 0001433607 (1433607). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find InspireMD, Inc.'s SEC filings?

All of InspireMD, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did InspireMD, Inc. last report earnings?

InspireMD, Inc. (NSPR) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-021105). This is InspireMD, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is InspireMD, Inc.'s most recent earnings 8-K?

InspireMD, Inc.'s latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001493152-26-021105. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View InspireMD, Inc.'s latest earnings 8-K →
Look up any company's CIK number →